Development Pipeline
| Indication | Development Stage |
|---|---|
| Hepatocellular Carcinoma | Phase III |
| Metastatic Colorectal Cancer | Phase III |
| Glioma | Phase II |
| Benign Prostatic Hyperplasia | Phase I |
Current Clinical Trials
Phase III trials are underway in hepatocellular carcinoma and colorectal cancer metastatic to the liver.
About Light Sciences Oncology
Light Sciences Oncology is developing Light Infusion Therapy™ (Litx™), an innovative light-activated drug treatment for solid tumors, designed to provide safer and more effective treatment to cancer patients. In addition to Phase III trials underway in hepatocellular carcinoma and colorectal cancer metastatic to the liver, the company has completed a Phase II clinical trial of Litx in glioma. LSO has expanded the scope of potential therapeutic applications of its versatile Litx platform to include benign neoplasms such as benign prostatic hyperplasia and uterine fibroids, as well as vascular disease and dermatology. The company has positioned itself for growth with a strong portfolio of intellectual property, innovative applications in development, and an exceptionally talented team.
Litx™ Therapy Animation
View animation of Litx™ therapy at work
Litx™ Therapy Animation
Light Sciences Oncology is developing Light Infusion Therapy™ (Litx™), an innovative light-activated treatment for solid tumors, to provide safer and more effective treatment to cancer patients. LSO has initiated late-stage clinical trials of Litx™ in the treatment of solid tumors.